Literature DB >> 9525595

The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks.

J A Lekstrom-Himes1, L Pesnicak, S E Straus.   

Abstract

Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) have evolved specific anatomic tropisms and site-dependent rates of reactivation. To determine whether reactivation rates depend on distinct abilities of HSV-1 and -2 to establish latency and to express latency-associated transcripts (LATs), virulent strains of each virus were studied in the guinea pig genital model. Following infection with equivalent titers of virus, the quantities of latent HSV-2 genomes and LATs were higher in lumbosacral ganglia, and HSV-2 infections recurred more frequently and lasted longer than HSV-1 infections. In contrast, if the inoculum of HSV-1 was 10 times that of HSV-2, the quantity of HSV-1 DNA and LATs increased correspondingly and HSV-1 infections were as likely to recur as those with HSV-2. The quantity of latent virus DNA correlates with and may be a major determinant of the site-specific patterns and rates of reactivation of HSV-1 and -2.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525595      PMCID: PMC109720     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Effect of immunization on the development of latent ganglionic infection in mice challenged intravaginally with herpes simplex virus types 1 and 2.

Authors:  L V Asher; M A Walz; A L Notkins
Journal:  Am J Obstet Gynecol       Date:  1978-08-01       Impact factor: 8.661

2.  Effect of immunization on acute and latent infections of vaginouterine tissue with herpes simplex virus types 1 and 2.

Authors:  M A Walz; R W Price; K Hayashi; B J Katz; A L Notkins
Journal:  J Infect Dis       Date:  1977-05       Impact factor: 5.226

3.  Outcome of herpes simplex virus type 2 infection in guinea pigs.

Authors:  S L Fowler; C J Harrison; M G Myers; L R Stanberry
Journal:  J Med Virol       Date:  1992-04       Impact factor: 2.327

4.  Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type.

Authors:  W E Lafferty; R W Coombs; J Benedetti; C Critchlow; L Corey
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

5.  A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency.

Authors:  D A Leib; C L Bogard; M Kosz-Vnenchak; K A Hicks; D M Coen; D M Knipe; P A Schaffer
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

6.  Herpes simplex virus type 1 DNA replication and gene expression during explant-induced reactivation of latently infected murine sensory ganglia.

Authors:  G B Devi-Rao; D C Bloom; J G Stevens; E K Wagner
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Effect of acyclovir on genital infection with herpes simplex virus types 1 and 2 in the guinea pig.

Authors:  M L Landry; H L Lucia; G D Hsiung; A D Pronovost; P R Dann; M J August; D R Mayo
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

8.  Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease.

Authors:  L R Stanberry; E R Kern; J T Richards; T M Abbott; J C Overall
Journal:  J Infect Dis       Date:  1982-09       Impact factor: 5.226

9.  Type 1 and type 2 herpes simplex viruses: serological and biological differences.

Authors:  G Plummer; J L Waner; A Phuangsab; C R Goodheart
Journal:  J Virol       Date:  1970-01       Impact factor: 5.103

10.  Herpes simplex virus type 1 latency-associated transcripts are evidently not essential for latent infection.

Authors:  I Steiner; J G Spivack; R P Lirette; S M Brown; A R MacLean; J H Subak-Sharpe; N W Fraser
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

View more
  31 in total

1.  Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice.

Authors:  Sarat K Dalai; Lesley Pesnicak; Georgina F Miller; Stephen E Straus
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

Review 2.  CD8+ T cells patrol HSV-1-infected trigeminal ganglia and prevent viral reactivation.

Authors:  Anthony J St Leger; Robert L Hendricks
Journal:  J Neurovirol       Date:  2011-12-08       Impact factor: 2.643

3.  Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.

Authors:  Christopher S Morello; Michael S Levinson; Kimberly A Kraynyak; Deborah H Spector
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

4.  Failure of thymidine kinase-negative herpes simplex virus to reactivate from latency following efficient establishment.

Authors:  Shih-Heng Chen; Angela Pearson; Donald M Coen; Shun-Hua Chen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  The number of herpes simplex virus-infected neurons and the number of viral genome copies per neuron correlate with the latent viral load in ganglia.

Authors:  Yo Hoshino; Jing Qin; Dean Follmann; Jeffrey I Cohen; Stephen E Straus
Journal:  Virology       Date:  2007-11-28       Impact factor: 3.616

6.  Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Authors:  Sita Awasthi; John M Lubinski; Carolyn E Shaw; Shana M Barrett; Michael Cai; Fushan Wang; Michael Betts; Susan Kingsley; Daniel J Distefano; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

7.  T cell response kinetics determines neuroinfection outcomes during murine HSV infection.

Authors:  Aisha G Lee; Jason M Scott; Maria Rita Fabbrizi; Xiaoping Jiang; Dorothy K Sojka; Mark J Miller; Megan T Baldridge; Wayne M Yokoyama; Haina Shin
Journal:  JCI Insight       Date:  2020-03-12

8.  Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.

Authors:  Yo Hoshino; Sarat K Dalai; Kening Wang; Lesley Pesnicak; Tsz Y Lau; David M Knipe; Jeffrey I Cohen; Stephen E Straus
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

9.  Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.

Authors:  Richard Brans; Feng Yao
Journal:  BMC Microbiol       Date:  2010-06-03       Impact factor: 3.605

10.  Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1.

Authors:  Richard Brans; Natali V Akhrameyeva; Feng Yao
Journal:  J Invest Dermatol       Date:  2009-04-09       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.